Enzalutamide Soft Capsules

DRUG2 trials

Sponsors

Jiangsu HengRui Medicine Co., Ltd.

Conditions

Advanced Prostate CancerMetastatic Hormone-sensitive Prostate Cancer (mHSPC)

Phase 1

Study of HRS-5041 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

RecruitingNCT05942001

Jiangsu HengRui Medicine Co., Ltd.Advanced Prostate Cancer

Start: 2023-08-03End: 2026-09-01Target: 100Updated: 2026-08-31

Phase 3

A Phase III Clinical Study of Rezvilutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer

RecruitingNCT07241416

Jiangsu HengRui Medicine Co., Ltd.Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Start: 2025-12-05End: 2028-09-01Target: 206Updated: 2026-05-11

Related Papers

HRS-5041, an androgen receptor degrader, in metastatic castration-resistant prostate cancer: A phase 1, multicenter, first-in-human study.

Journal of Clinical Oncology2026-05-27